MRNA

Moderna Inc. trades at a market capitalization of $19.5B while navigating a significant post-pandemic revenue transition, with current-year revenue declining 29.97% year-over-year. The systematic screening highlights a company operating at substantially negative profitability margins: ROE of -36.73%, ROA of -26.63%, and a net margin of -143.55%. Per-share losses stand at $8.15, reflecting the fundamental challenge of maintaining operations as COVID-19 vaccine demand normalizes.

The valuation framework reveals distinctive characteristics relative to traditional biotech metrics. The price-to-sales ratio of 8.75 reflects residual commercial revenue generation, while the price-to-book of 1.33 sits near tangible equity value, with book value per share at $21.95. The current share price of $48.11 positions the company 19.2% below its 52-week high of $59.55 but substantially above the $22.28 low point reached during broader market skepticism.

Balance sheet screening identifies specific strengths:

• Conservative capital structure with a debt-to-equity ratio of just 0.07, providing financial flexibility for R&D investments
• Current ratio of 3.29 indicates robust short-term liquidity despite operational cash burn
• Gross margin of 35.01% demonstrates retained pricing power on existing product portfolio

Risk factors center on the operational margin deterioration to -153.35%, suggesting substantial investment in pipeline development without offsetting revenue. Relative to peers BIIB, NTRA, and UTHR, Moderna's research perspective emphasizes a platform technology model rather than diversified revenue streams. The beta of 1.04 indicates market-level volatility exposure as the company executes its clinical-stage transition strategy.